Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P01185

UPID:
NEU2_HUMAN

ALTERNATIVE NAMES:
AVP-NPII

ALTERNATIVE UPACC:
P01185; A0AV35; O14935

BACKGROUND:
The protein Vasopressin-neurophysin 2-copeptin, with alternative name AVP-NPII, is pivotal in maintaining fluid balance and blood pressure. It binds vasopressin, influencing kidney function and blood vessel constriction through interaction with specific receptors. Its role underscores the complexity of the body's regulatory mechanisms for water and vascular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Linked to Diabetes insipidus, neurohypophyseal, Vasopressin-neurophysin 2-copeptin's dysfunction manifests in significant hydration and urinary challenges. Targeting this protein's pathway offers a promising avenue for therapeutic intervention in treating vasopressin-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.